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Introduction
Lung cancer is currently the most common type of cancer affecting both men and women, owing to the high prevalence of smoking worldwide. 1, 2 According to the American Cancer Society, lung cancer was the leading cause of cancer-related mortality in 2016 in the United States of America, with estimated 158,080 deaths (~27%). 3 Conventional treatments against cancer, such as surgery and radiation therapy, are not feasible in advanced lung cancer mainly owing to the location of the cancer cells in the body. 4 Chemotherapy is an effective systemic treatment option; chemotherapeutic drugs can disrupt the cell cycle/division and angiogenesis or induce apoptosis of cancer cells through several signaling pathways. 5 Nevertheless, owing to the high rate of cancer-related mortality, development of resistance, and occurrence of serious adverse effects, continuous efforts are exerted by scientists to develop new drugs for the treatment of cancer. 6 Xanthones are bioactive substances isolated and extracted from plants and microorganisms. 7 Their basic skeleton had been confirmed as a biphenyl pyranone with a planar three-ring structure ( Figure 1A) . Notably, the derivatives of xanthone possess an array of pharmacological activities (e.g., antitumor, antibacterial, antioxidant, hypolipidemic, etc.). 8, 9 Based on their planar structure, they act as efficient DNA intercalators and show anticancer activity via non-covalent DNA interaction. 10 Previous studies have reported structures of natural xanthones, such as 5,6-dimethylxanthone-4-acetic acid (DMXAA; IC 50 = 48.4 μM for MDA-MB-231 cells) ( Figure 1 ) and globosuxanthone A, which showed outstanding anti-proliferative activity. 11, 12 In particular, DMXAA can interact with various biological targets via diverse actions. DMXAA is currently entering the phase III clinical trial stage; consequently, the synthesis of xanthone derivatives with excellent anticancer activity has attracted considerable attention. A series of xanthone analogues were reported and demonstrated improved in vitro antitumor activity versus the parent xanthone and drug-like properties. 13, 14 For example, a caged xanthone ( Figure 1B ; IC 50 = 3.60 μM for A549 cells) was synthesized using the prenyl moiety of its parent xanthone, 15, 16 while 3-phenylxanthone ( Figure 1C ; IC 50 = 6.27 μM for QGY-7703 cells) was identified as a potent and promising antitumor agent. 17 In the side chain, 1,2,3-triazole could serve as a privileged building block for the synthesis of bioconjugates owing to its high stability, selectivity, and fewer adverse reactions. 18 It exhibited formidable stability under basic and acid hydrolysis, including oxidative and reductive reactions. Moreover, this heterocycle was the bioisostere of amide and interacted with biomolecular targets through hydrogen-bonding. 19 This attractive chromophore showed diverse activities (e.g., antibacterial, antiallergic, antiviral, antimalarial, antifungal, and anticancer). [20] [21] [22] [23] [24] In addition, it interacted with DNA and acted as a supporting motif for DNA targeting compounds, such as xanthones. 25, 26 Cu(I)catalyzed azide-alkyne cycloaddition (Click Reaction) rapidly yields bioactive molecules linked through 1,2,3-triazole with high atom economy, and have been widely applied to combinatorial synthesis and bio-conjugate chemistry. 27 However, to the best of our knowledge, the incorporation of the polar 1,2,3-triazole ring located at the C3-position of xanthone has not been reported in prior studies. Therefore, 22 heterocyclic xanthone derivatives were designed and synthesized to explore the antiproliferative effect associated with the 1,2,3-triazole and substituent benzyls of the xanthone framework (1a-v, Figure 1 ). The antiproliferative effects of all derivatives were evaluated in vitro using the MTT colorimetric method against human lung cancer cell line A549. 28, 29 Furthermore, we carefully selected potential compounds to examine the main mechanism involved in cancer cell death.
Materials and Methods Chemistry
Target compounds 1a-v were synthesized on the basis of a reasonable synthetic route strategy (Scheme 1). In this method, synthesis of compound 4 was achieved by applying Eaton's reagents starting from 2-hydroxybenzoic acid 2 and 1, 3, 5-trihydroxybenzene 3. Compound 5 was synthesized through the O-alkylation reaction, in the presence of K 2 CO 3 , KI, and propargyl bromide in acetonitrile at room temperature. The target compounds 1a-v were obtained by performing a click reaction with variously substituted benzyl azides. All compounds were characterized through 1 H NMR, 13 C NMR, and MS. The details are provided in the Supplementary Information of this article.
Biological Assays
We used the methyl thiazolyl tetrazolium (MTT) method to measure the cytotoxic activity of the target compounds against human lung cancer A549 cells. The results of this experiment are summarized in Table 1 . 28, 29 The A549 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were seeded at a density of 5×10 4 cells/mL, and the compounds were added to the supernatant at different concentrations (i.e., 50 μg/mL, 30 μg/mL, 10 μg/mL, 2 μg/mL, 0.4 μg/mL). Cells not treated with compounds served as negative control, while those treated with pirarubicin hydrochloride served as positive control. Twelve hours later, MTT (20 μL, 5 mg/mL) was added to the cells, and the cells were incubated at 37°C for 4 h in the dark. Subsequently, dimethyl sulfoxide was added and the mixture was incubated for 10 min. All compounds were incubated with A549 cells for 12 h. The absorbance was measured at 490 nm using a microplate reader (Multiskan MK3, Thermo Scientific, USA). Cell survival in the control group was considered 100% and that of all other groups was normalized to this value. These procedures were performed in triplicate.
Western blotting was performed to separate the proteins. For the extraction of total protein, 5×10 5 A549 cells were lysed in Protein Extraction Regent (Pierce, Rockford, USA) supplemented with a protease inhibitor cocktail and centrifuged (17,709 g) for 15 min at 4°C. Protein concentrations of the extracts were measured using the BCA assay (Pierce, Rockford, IL, USA) and equalized with the extraction reagent. Proteins were separated through sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Millipore, MA, USA). After the transfer, the proteins were immunoblotted with the corresponding primary antibody against caspase 3, p53, Bax, and c-Jun N-terminal kinase (JNK) (Cell Signaling Technology, Danvers, MA, USA) (dilution ratio: 1:5000). The blots were incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (Kangchen, Shanghai, China) for 1 h at room temperature (dilution ratio: 1:5000). The intensity of each protein band was measured using Quantity One.
A549 cells (1×10 5 cells/mL) were seeded in six-well plates and treated with either vehicle or the indicated concentrations of 1j and 1h for 48 hr. The cells were collected through centrifugation at 4°C and washed twice with ice-cold phosphate-buffered saline. Subsequently, the cells were stained with Annexin-V-FITC/PI (KeyGEN; Nanjing, China) and analyzed via flow cytometry (BD FACS Calibur, Franklin Lakes, CA, USA).
Statistical Analysis
Data are presented as means ± standard deviation. One-way analysis of variance was used to calculate statistical differences. All statistical analyses in this study were conducted using SPSS for Windows, version 22.0 (IBM, Armonk, NY, USA). A p<0.05 denoted statistical significance.
Results and Discussion
As shown in Table 1 , 22 target compounds were synthesized after the introduction of 1,2,3-triazole and the heterocycle group. Of those, 18 compounds showed higher activity compared with intermediate 4 (IC 50 = 340.7 ± 4.8 μM) and 5 (IC 50 = 268.4 ± 3.5 μM). The extensional structure of various substituted groups resulted in a significantly demonstrated the highest activity in this series. Among compounds with substituted halogen, the compound with replaced para bromide exhibited the highest anticancer activity (IC 50 = 32.4 ± 2.2 μM). However, the IC 50 values of compounds 1a-v were lower than that of pirarubicin hydrochloride, an effective anticancer drug used in clinical practice. Two representative compounds, namely 1h (IC 50 = 40.2 ± 3.8 μM) and 1j (IC 50 = 32.4 ± 2.2 μM), presented strong activity against lung cancer A549 cells. In addition, these compounds obviously decreased the survival rate of human umbilical vein endothelial cells, and resulted in toxic effects on normal cells at concentrations of 46 μM and 34 μM, respectively (Figure 2 ). Owing to their higher activity against cancer cells, compounds 1h (low dose: 10 μg/mL, 23 μM, high dose:
20 μg/mL, 46 μM) and 1j (low dose: 8 μg/mL, 17 μM; high dose: 16 μg/mL, 34 μM) were selected for further evaluation. Firstly, their effect of these compounds on apoptosis was investigated. Two doses (low dose, high dose) were used in the experiment and the results are presented in Figure 3 . At the low dose, the rate of total apoptosis induced by 1h and 1j was only 12.21% and 11.18%, respectively. Notably, at the high dose, 1j resulted in 24.20% and 17.59% total and later apoptosis, respectively. The effect of 1h on later apoptosis also markedly contributed to cell death (19.93%). There was no significant difference between the low and high dose groups in terms of early apoptosis. Furthermore, A549 cells were incubated with 1h (46 μM) and 1j (34 μM) for 72 h. The rate of total apoptosis increased with time ( Figure 4 ). We used Western blotting to examine the expression of caspase 3, p53, Bax, and JNK in A549 cells after incubation with 1h and 1j for 12 h to disclose the mechanism through which compounds 1h and 1j prevented cancer cell growth. Caspase-3 was involved in the apoptotic process (i.e., chromatin condensation and DNA fragmentation). JNK played key roles in regulating cell proliferation, apoptosis, and differentiation. As shown in Figure 5 , we found that both compounds 1j and 1h increased the expression of caspase-3 and JNK in A549 cells. Interestingly, these two compounds also enhanced the expression of p53. p53 is a tumor suppressor playing numerous roles in inducing DNA repair, senescence, cell cycle arrest, and apoptosis. This result was consistent with those of previous studies investigating other series of xanthone. 30, 31 Noticeably, only compound 1j significantly up-regulated the expression of Bax protein. Bax, belonging to the Bcl-2 gene family, was central to the regulation of mitochondrial apoptosis. Collectively, these findings suggest that the high expression of apoptosis-related factors and p53 was the main mechanism of compound 1j.
Conclusion
Most of the target compounds exerted a marked inhibitory effect on cancer cells. The activity of 18 compounds was higher than that of the intermediates 4 and 5. Moreover, the extensional structure of the 1,2,3-triazole ring and heterocycle groups was beneficial to anticancer activity. Compounds 1h and 1j demonstrated the most potent inhibitory activity against A549 cells. The effects of compounds 1h and 1j on early apoptosis, necrosis, and late apoptosis were similar. The results of the Western blotting analysis indicated that compound 1j increased the expression of caspase 3, JNK, p53, and particularly Bax, providing a novel viewpoint of the effects of xanthone derivatives. 
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